1
|
Exploiting Vitamin D Receptor and Its Ligands to Target Squamous Cell Carcinomas of the Head and Neck. Int J Mol Sci 2023; 24:ijms24054675. [PMID: 36902107 PMCID: PMC10002563 DOI: 10.3390/ijms24054675] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2023] [Revised: 02/17/2023] [Accepted: 02/27/2023] [Indexed: 03/06/2023] Open
Abstract
Vitamin D (VitD) and its receptor (VDR) have been intensively investigated in many cancers. As knowledge for head and neck cancer (HNC) is limited, we investigated the (pre)clinical and therapeutic relevance of the VDR/VitD-axis. We found that VDR was differentially expressed in HNC tumors, correlating to the patients' clinical parameters. Poorly differentiated tumors showed high VDR and Ki67 expression, whereas the VDR and Ki67 levels decreased from moderate to well-differentiated tumors. The VitD serum levels were lowest in patients with poorly differentiated cancers (4.1 ± 0.5 ng/mL), increasing from moderate (7.3 ± 4.3 ng/mL) to well-differentiated (13.2 ± 3.4 ng/mL) tumors. Notably, females showed higher VitD insufficiency compared to males, correlating with poor differentiation of the tumor. To mechanistically uncover VDR/VitD's pathophysiological relevance, we demonstrated that VitD induced VDR nuclear-translocation (VitD < 100 nM) in HNC cells. RNA sequencing and heat map analysis showed that various nuclear receptors were differentially expressed in cisplatin-resistant versus sensitive HNC cells including VDR and the VDR interaction partner retinoic acid receptor (RXR). However, RXR expression was not significantly correlated with the clinical parameters, and cotreatment with its ligand, retinoic acid, did not enhance the killing by cisplatin. Moreover, the Chou-Talalay algorithm uncovered that VitD/cisplatin combinations synergistically killed tumor cells (VitD < 100 nM) and also inhibited the PI3K/Akt/mTOR pathway. Importantly, these findings were confirmed in 3D-tumor-spheroid models mimicking the patients' tumor microarchitecture. Here, VitD already affected the 3D-tumor-spheroid formation, which was not seen in the 2D-cultures. We conclude that novel VDR/VitD-targeted drug combinations and nuclear receptors should also be intensely explored for HNC. Gender-specific VDR/VitD-effects may be correlated to socioeconomic differences and need to be considered during VitD (supplementation)-therapies.
Collapse
|
2
|
Gerlt V, Mayr J, Del Sarto J, Ludwig S, Boergeling Y. Cellular Protein Phosphatase 2A Regulates Cell Survival Mechanisms in Influenza A Virus Infection. Int J Mol Sci 2021; 22:11164. [PMID: 34681823 PMCID: PMC8540457 DOI: 10.3390/ijms222011164] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Revised: 10/08/2021] [Accepted: 10/11/2021] [Indexed: 12/12/2022] Open
Abstract
Influenza A viruses (IAVs) are respiratory pathogens that are able to hijack multiple cellular mechanisms to drive their replication. Consequently, several viral and cellular proteins undergo posttranslational modifications such as dynamic phosphorylation/dephosphorylation. In eukaryotic cells, dephosphorylation is mainly catalyzed by protein phosphatase 2A (PP2A). While the function of kinases in IAV infection is quite well studied, only little is known about the role of PP2A in IAV replication. Here, we show, by using knockdown and inhibition approaches of the catalytic subunit PP2Ac, that this phosphatase is important for efficient replication of several IAV subtypes. This could neither be attributed to alterations in the antiviral immune response nor to changes in transcription or translation of viral genes. Interestingly, decreased PP2Ac levels resulted in a significantly reduced cell viability after IAV infection. Comprehensive kinase activity profiling identified an enrichment of process networks related to apoptosis and indicated a synergistic action of hyper-activated PI3K/Akt, MAPK/JAK-STAT and NF-kB signaling pathways, collectively resulting in increased cell death. Taken together, while IAV seems to effectively tap leftover PP2A activity to ensure efficient viral replication, reduced PP2Ac levels fail to orchestrate cell survival mechanisms to protect infected cells from early cell death.
Collapse
Affiliation(s)
- Vanessa Gerlt
- Institute of Virology Muenster, University of Muenster, 48149 Muenster, Germany; (V.G.); (J.M.); (J.D.S.); (S.L.)
| | - Juliane Mayr
- Institute of Virology Muenster, University of Muenster, 48149 Muenster, Germany; (V.G.); (J.M.); (J.D.S.); (S.L.)
| | - Juliana Del Sarto
- Institute of Virology Muenster, University of Muenster, 48149 Muenster, Germany; (V.G.); (J.M.); (J.D.S.); (S.L.)
- Department of Neurology, Institute of Translational Neurology, Medical Faculty, University Hospital Muenster, 48149 Muenster, Germany
| | - Stephan Ludwig
- Institute of Virology Muenster, University of Muenster, 48149 Muenster, Germany; (V.G.); (J.M.); (J.D.S.); (S.L.)
| | - Yvonne Boergeling
- Institute of Virology Muenster, University of Muenster, 48149 Muenster, Germany; (V.G.); (J.M.); (J.D.S.); (S.L.)
| |
Collapse
|
3
|
Shaikhqasem A, Schmitt K, Valerius O, Ficner R. Crystal structure of human CRM1, covalently modified by 2-mercaptoethanol on Cys528, in complex with RanGTP. Acta Crystallogr F Struct Biol Commun 2021; 77:70-78. [PMID: 33682791 PMCID: PMC7938638 DOI: 10.1107/s2053230x2100203x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2021] [Accepted: 02/21/2021] [Indexed: 11/23/2022] Open
Abstract
CRM1 is a nuclear export receptor that has been intensively targeted over the last decade for the development of antitumor and antiviral drugs. Structural analysis of several inhibitor compounds bound to CRM1 revealed that their mechanism of action relies on the covalent modification of a critical cysteine residue (Cys528 in the human receptor) located in the nuclear export signal-binding cleft. This study presents the crystal structure of human CRM1, covalently modified by 2-mercaptoethanol on Cys528, in complex with RanGTP at 2.58 Å resolution. The results demonstrate that buffer components can interfere with the characterization of cysteine-dependent inhibitor compounds.
Collapse
Affiliation(s)
- Alaa Shaikhqasem
- Department for Molecular Structural Biology, Georg-August-Universität Göttingen, Justus-von-Liebig Weg 11, 37077 Göttingen, Germany
| | - Kerstin Schmitt
- Department of Molecular Microbiology and Genetics, Georg-August-Universität Göttingen, Grisebachstrasse 8, 37077 Göttingen, Germany
| | - Oliver Valerius
- Department of Molecular Microbiology and Genetics, Georg-August-Universität Göttingen, Grisebachstrasse 8, 37077 Göttingen, Germany
| | - Ralf Ficner
- Department for Molecular Structural Biology, Georg-August-Universität Göttingen, Justus-von-Liebig Weg 11, 37077 Göttingen, Germany
| |
Collapse
|
4
|
Sendino M, Omaetxebarria MJ, Prieto G, Rodriguez JA. Using a Simple Cellular Assay to Map NES Motifs in Cancer-Related Proteins, Gain Insight into CRM1-Mediated NES Export, and Search for NES-Harboring Micropeptides. Int J Mol Sci 2020; 21:E6341. [PMID: 32882917 PMCID: PMC7503480 DOI: 10.3390/ijms21176341] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2020] [Revised: 08/24/2020] [Accepted: 08/26/2020] [Indexed: 12/26/2022] Open
Abstract
The nuclear export receptor CRM1 (XPO1) recognizes and binds specific sequence motifs termed nuclear export signals (NESs) in cargo proteins. About 200 NES motifs have been identified, but over a thousand human proteins are potential CRM1 cargos, and most of their NESs remain to be identified. On the other hand, the interaction of NES peptides with the "NES-binding groove" of CRM1 was studied in detail using structural and biochemical analyses, but a better understanding of CRM1 function requires further investigation of how the results from these in vitro studies translate into actual NES export in a cellular context. Here we show that a simple cellular assay, based on a recently described reporter (SRVB/A), can be applied to identify novel potential NESs motifs, and to obtain relevant information on different aspects of CRM1-mediated NES export. Using cellular assays, we first map 19 new sequence motifs with nuclear export activity in 14 cancer-related proteins that are potential CRM1 cargos. Next, we investigate the effect of mutations in individual NES-binding groove residues, providing further insight into CRM1-mediated NES export. Finally, we extend the search for CRM1-dependent NESs to a recently uncovered, but potentially vast, set of small proteins called micropeptides. By doing so, we report the first NES-harboring human micropeptides.
Collapse
Affiliation(s)
- Maria Sendino
- Department of Genetics, Physical Anthropology and Animal Physiology, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain;
| | - Miren Josu Omaetxebarria
- Department of Biochemistry and Molecular Biology, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain;
| | - Gorka Prieto
- Department of Communications Engineering, University of the Basque Country (UPV/EHU), 48013 Bilbao, Spain;
| | - Jose Antonio Rodriguez
- Department of Genetics, Physical Anthropology and Animal Physiology, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain;
| |
Collapse
|
5
|
Shaikhqasem A, Dickmanns A, Neumann P, Ficner R. Characterization of Inhibition Reveals Distinctive Properties for Human and Saccharomyces cerevisiae CRM1. J Med Chem 2020; 63:7545-7558. [PMID: 32585100 DOI: 10.1021/acs.jmedchem.0c00143] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
The receptor CRM1 is responsible for the nuclear export of many tumor-suppressor proteins and viral ribonucleoproteins. This renders CRM1 an interesting target for therapeutic intervention in diverse cancer types and viral diseases. Structural studies of Saccharomyces cerevisiae CRM1 (ScCRM1) complexes with inhibitors defined the molecular basis for CRM1 inhibition. Nevertheless, no structural information is available for inhibitors bound to human CRM1 (HsCRM1). Here, we present the structure of the natural inhibitor Leptomycin B bound to the HsCRM1-RanGTP complex. Despite high sequence conservation and structural similarity in the NES-binding cleft region, ScCRM1 exhibits 16-fold lower binding affinity than HsCRM1 toward PKI-NES and significant differences in affinities toward potential CRM1 inhibitors. In contrast to HsCRM1, competition assays revealed that a human adapted mutant ScCRM1-T539C does not bind all inhibitors tested. Taken together, our data indicate the importance of using HsCRM1 for molecular analysis and development of novel antitumor and antiviral drugs.
Collapse
Affiliation(s)
- Alaa Shaikhqasem
- Department of Molecular Structural Biology, Institute of Microbiology and Genetics, GZMB, Georg-August-University Göttingen, 37077 Göttingen, Germany
| | - Achim Dickmanns
- Department of Molecular Structural Biology, Institute of Microbiology and Genetics, GZMB, Georg-August-University Göttingen, 37077 Göttingen, Germany
| | - Piotr Neumann
- Department of Molecular Structural Biology, Institute of Microbiology and Genetics, GZMB, Georg-August-University Göttingen, 37077 Göttingen, Germany
| | - Ralf Ficner
- Department of Molecular Structural Biology, Institute of Microbiology and Genetics, GZMB, Georg-August-University Göttingen, 37077 Göttingen, Germany
| |
Collapse
|
6
|
Mistriotis P, Wisniewski EO, Bera K, Keys J, Li Y, Tuntithavornwat S, Law RA, Perez-Gonzalez NA, Erdogmus E, Zhang Y, Zhao R, Sun SX, Kalab P, Lammerding J, Konstantopoulos K. Confinement hinders motility by inducing RhoA-mediated nuclear influx, volume expansion, and blebbing. J Cell Biol 2019; 218:4093-4111. [PMID: 31690619 PMCID: PMC6891075 DOI: 10.1083/jcb.201902057] [Citation(s) in RCA: 56] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2019] [Revised: 05/28/2019] [Accepted: 09/18/2019] [Indexed: 11/22/2022] Open
Abstract
Cells migrate in vivo through complex confining microenvironments, which induce significant nuclear deformation that may lead to nuclear blebbing and nuclear envelope rupture. While actomyosin contractility has been implicated in regulating nuclear envelope integrity, the exact mechanism remains unknown. Here, we argue that confinement-induced activation of RhoA/myosin-II contractility, coupled with LINC complex-dependent nuclear anchoring at the cell posterior, locally increases cytoplasmic pressure and promotes passive influx of cytoplasmic constituents into the nucleus without altering nuclear efflux. Elevated nuclear influx is accompanied by nuclear volume expansion, blebbing, and rupture, ultimately resulting in reduced cell motility. Moreover, inhibition of nuclear efflux is sufficient to increase nuclear volume and blebbing on two-dimensional surfaces, and acts synergistically with RhoA/myosin-II contractility to further augment blebbing in confinement. Cumulatively, confinement regulates nuclear size, nuclear integrity, and cell motility by perturbing nuclear flux homeostasis via a RhoA-dependent pathway.
Collapse
Affiliation(s)
- Panagiotis Mistriotis
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD.,Johns Hopkins Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD
| | - Emily O Wisniewski
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD.,Johns Hopkins Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD
| | - Kaustav Bera
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD.,Johns Hopkins Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD
| | - Jeremy Keys
- Meinig School of Biomedical Engineering and Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY
| | - Yizeng Li
- Johns Hopkins Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD.,Department of Mechanical Engineering, Johns Hopkins University, Baltimore, MD.,Department of Mechanical Engineering, Kennesaw State University, Marietta, GA
| | - Soontorn Tuntithavornwat
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD.,Johns Hopkins Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD
| | - Robert A Law
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD.,Johns Hopkins Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD
| | - Nicolas A Perez-Gonzalez
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD.,Johns Hopkins Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD
| | - Eda Erdogmus
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD
| | - Yuqi Zhang
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD.,Johns Hopkins Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD
| | - Runchen Zhao
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD.,Johns Hopkins Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD
| | - Sean X Sun
- Johns Hopkins Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD.,Department of Mechanical Engineering, Johns Hopkins University, Baltimore, MD.,Johns Hopkins Physical Sciences-Oncology Center, Johns Hopkins University, Baltimore, MD.,Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD
| | - Petr Kalab
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD.,Johns Hopkins Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD
| | - Jan Lammerding
- Meinig School of Biomedical Engineering and Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY
| | - Konstantinos Konstantopoulos
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD .,Johns Hopkins Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD.,Department of Mechanical Engineering, Johns Hopkins University, Baltimore, MD.,Johns Hopkins Physical Sciences-Oncology Center, Johns Hopkins University, Baltimore, MD.,Department of Oncology, Johns Hopkins University, Baltimore, MD
| |
Collapse
|
7
|
Klahn P, Fetz V, Ritter A, Collisi W, Hinkelmann B, Arnold T, Tegge W, Rox K, Hüttel S, Mohr KI, Wink J, Stadler M, Wissing J, Jänsch L, Brönstrup M. The nuclear export inhibitor aminoratjadone is a potent effector in extracellular-targeted drug conjugates. Chem Sci 2019; 10:5197-5210. [PMID: 31191875 PMCID: PMC6540907 DOI: 10.1039/c8sc05542d] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2018] [Accepted: 04/15/2019] [Indexed: 12/04/2022] Open
Abstract
The concept of targeted drug conjugates has been successfully translated to clinical practice in oncology. Whereas the majority of cytotoxic effectors in drug conjugates are directed against either DNA or tubulin, our study aimed to validate nuclear export inhibition as a novel effector principle in drug conjugates. For this purpose, a semisynthetic route starting from the natural product ratjadone A, a potent nuclear export inhibitor, has been developed. The biological evaluation of ratjadones functionalized at the 16-position revealed that oxo- and amino-analogues had very high potencies against cancer cell lines (e.g. 16R-aminoratjadone 16 with IC50 = 260 pM against MCF-7 cells, or 19-oxoratjadone 14 with IC50 = 100 pM against A-549 cells). Mechanistically, the conjugates retained a nuclear export inhibitory activity through binding CRM1. To demonstrate a proof-of-principle for cellular targeting, folate- and luteinizing hormone releasing hormone (LHRH)-based carrier molecules were synthesized and coupled to aminoratjadones as well as fluorescein for cellular efficacy and imaging studies, respectively. The Trojan-Horse conjugates selectively addressed receptor-positive cell lines and were highly potent inhibitors of their proliferation. For example, the folate conjugate FA-7-Val-Cit-pABA-16R-aminoratjadone had an IC50 of 34.3 nM, and the LHRH conjugate d-Orn-Gose-Val-Cit-pABA-16R-aminoratjadone had an IC50 of 12.8 nM. The results demonstrate that nuclear export inhibition is a promising mode-of-action for extracellular-targeted drug conjugate payloads.
Collapse
Affiliation(s)
- Philipp Klahn
- Department of Chemical Biology , Helmholtz Centre for Infection Research , Inhoffenstrasse 7 , 38124 Braunschweig , Germany .
- Institute of Organic Chemistry , Technische Universität Braunschweig , Hagenring 30 , 38106 Braunschweig , Germany .
| | - Verena Fetz
- Department of Chemical Biology , Helmholtz Centre for Infection Research , Inhoffenstrasse 7 , 38124 Braunschweig , Germany .
| | - Antje Ritter
- Department of Chemical Biology , Helmholtz Centre for Infection Research , Inhoffenstrasse 7 , 38124 Braunschweig , Germany .
| | - Wera Collisi
- Department of Chemical Biology , Helmholtz Centre for Infection Research , Inhoffenstrasse 7 , 38124 Braunschweig , Germany .
- Department of Microbial Drugs , Helmholtz Centre for Infection Research , Inhoffenstrasse 7 , 38124 Braunschweig , Germany
| | - Bettina Hinkelmann
- Department of Chemical Biology , Helmholtz Centre for Infection Research , Inhoffenstrasse 7 , 38124 Braunschweig , Germany .
| | - Tatjana Arnold
- Department of Chemical Biology , Helmholtz Centre for Infection Research , Inhoffenstrasse 7 , 38124 Braunschweig , Germany .
| | - Werner Tegge
- Department of Chemical Biology , Helmholtz Centre for Infection Research , Inhoffenstrasse 7 , 38124 Braunschweig , Germany .
| | - Katharina Rox
- Department of Chemical Biology , Helmholtz Centre for Infection Research , Inhoffenstrasse 7 , 38124 Braunschweig , Germany .
- German Centre of Infection Research (DZIF) , Partner Site Hannover-Braunschweig , Germany
| | - Stephan Hüttel
- Department of Microbial Drugs , Helmholtz Centre for Infection Research , Inhoffenstrasse 7 , 38124 Braunschweig , Germany
| | - Kathrin I Mohr
- Department of Microbial Drugs , Helmholtz Centre for Infection Research , Inhoffenstrasse 7 , 38124 Braunschweig , Germany
| | - Joachim Wink
- Department of Microbial Drugs , Helmholtz Centre for Infection Research , Inhoffenstrasse 7 , 38124 Braunschweig , Germany
| | - Marc Stadler
- Department of Microbial Drugs , Helmholtz Centre for Infection Research , Inhoffenstrasse 7 , 38124 Braunschweig , Germany
| | - Josef Wissing
- Department of Structure and Function of Proteins , Research Group Cellular Proteomic , Helmholtz Centre for Infection Research , Inhoffenstrasse 7 , 38124 Braunschweig , Germany
| | - Lothar Jänsch
- Department of Structure and Function of Proteins , Research Group Cellular Proteomic , Helmholtz Centre for Infection Research , Inhoffenstrasse 7 , 38124 Braunschweig , Germany
| | - Mark Brönstrup
- Department of Chemical Biology , Helmholtz Centre for Infection Research , Inhoffenstrasse 7 , 38124 Braunschweig , Germany .
- Biomolecular Drug Research Center (BMWZ) , Schneiderberg 38 , 30167 Hannover , Germany
- German Centre of Infection Research (DZIF) , Partner Site Hannover-Braunschweig , Germany
| |
Collapse
|
8
|
Mouton-Liger F, Rosazza T, Sepulveda-Diaz J, Ieang A, Hassoun SM, Claire E, Mangone G, Brice A, Michel PP, Corvol JC, Corti O. Parkin deficiency modulates NLRP3 inflammasome activation by attenuating an A20-dependent negative feedback loop. Glia 2018; 66:1736-1751. [PMID: 29665074 PMCID: PMC6190839 DOI: 10.1002/glia.23337] [Citation(s) in RCA: 98] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2018] [Revised: 03/16/2018] [Accepted: 03/19/2018] [Indexed: 12/13/2022]
Abstract
Neuroinflammation and mitochondrial dysfunction, key mechanisms in the
pathogenesis of Parkinson's disease (PD), are usually explored independently.
Loss‐of‐function mutations of PARK2 and PARK6,
encoding the E3 ubiquitin protein ligase Parkin and the mitochondrial
serine/threonine kinase PINK1, account for a large proportion of cases of autosomal
recessive early‐onset PD. PINK1 and Parkin regulate mitochondrial quality control and
have been linked to the modulation of innate immunity pathways. We report here an
exacerbation of NLRP3 inflammasome activation by specific inducers in microglia and
bone marrow‐derived macrophages from Park2−/− and Pink1−/− mice. The caspase 1‐dependent release of IL‐1β and IL‐18 was, therefore,
enhanced in Park2−/− and Pink1−/− cells. This defect was confirmed in blood‐derived macrophages from patients
with PARK2 mutations and was reversed by MCC950, which specifically
inhibits NLRP3 inflammasome complex formation. Enhanced NLRP3 signaling in
Parkin‐deficient cells was accompanied by a lack of induction of A20, a well‐known
negative regulator of the NF‐κB pathway recently shown to attenuate NLRP3
inflammasome activity. We also found an inverse correlation between A20 abundance and
IL‐1β release, in human macrophages challenged with NLRP3 inflammasome inducers.
Overall, our observations suggest that the A20/NLRP3‐inflammasome axis participates
in the pathogenesis of PARK2‐linked PD, paving the way for the
exploration of its potential as a biomarker and treatment target.
Collapse
Affiliation(s)
- François Mouton-Liger
- Institut du Cerveau et de la Moelle épinière, ICM, Paris, F-75013, France.,Inserm, U1127, Paris, F-75013, France.,CNRS, UMR 7225, Paris, F-75013, France.,Sorbonne Universités, Paris, F-75013, France
| | - Thibault Rosazza
- Institut du Cerveau et de la Moelle épinière, ICM, Paris, F-75013, France.,Inserm, U1127, Paris, F-75013, France.,CNRS, UMR 7225, Paris, F-75013, France.,Sorbonne Universités, Paris, F-75013, France
| | - Julia Sepulveda-Diaz
- Institut du Cerveau et de la Moelle épinière, ICM, Paris, F-75013, France.,Inserm, U1127, Paris, F-75013, France.,CNRS, UMR 7225, Paris, F-75013, France.,Sorbonne Universités, Paris, F-75013, France
| | - Amélie Ieang
- Institut du Cerveau et de la Moelle épinière, ICM, Paris, F-75013, France.,Inserm, U1127, Paris, F-75013, France.,CNRS, UMR 7225, Paris, F-75013, France.,Sorbonne Universités, Paris, F-75013, France
| | - Sidi-Mohamed Hassoun
- Institut du Cerveau et de la Moelle épinière, ICM, Paris, F-75013, France.,Inserm, U1127, Paris, F-75013, France.,CNRS, UMR 7225, Paris, F-75013, France.,Sorbonne Universités, Paris, F-75013, France
| | - Emilie Claire
- Institut du Cerveau et de la Moelle épinière, ICM, Paris, F-75013, France.,Inserm, U1127, Paris, F-75013, France.,CNRS, UMR 7225, Paris, F-75013, France.,Sorbonne Universités, Paris, F-75013, France
| | - Graziella Mangone
- Institut du Cerveau et de la Moelle épinière, ICM, Paris, F-75013, France.,Inserm, U1127, Paris, F-75013, France.,CNRS, UMR 7225, Paris, F-75013, France.,Sorbonne Universités, Paris, F-75013, France.,AP-HP, Hôpital de la Pitié Salpêtrière, Clinical Investigation Center of Neurology (CIC-1422), Department of Neurology, Hôpital Pitié-Salpêtrière, Paris, F-75013, France
| | - Alexis Brice
- Institut du Cerveau et de la Moelle épinière, ICM, Paris, F-75013, France.,Inserm, U1127, Paris, F-75013, France.,CNRS, UMR 7225, Paris, F-75013, France.,Sorbonne Universités, Paris, F-75013, France
| | - Patrick P Michel
- Institut du Cerveau et de la Moelle épinière, ICM, Paris, F-75013, France.,Inserm, U1127, Paris, F-75013, France.,CNRS, UMR 7225, Paris, F-75013, France.,Sorbonne Universités, Paris, F-75013, France
| | - Jean-Christophe Corvol
- Institut du Cerveau et de la Moelle épinière, ICM, Paris, F-75013, France.,Inserm, U1127, Paris, F-75013, France.,CNRS, UMR 7225, Paris, F-75013, France.,Sorbonne Universités, Paris, F-75013, France.,AP-HP, Hôpital de la Pitié Salpêtrière, Clinical Investigation Center of Neurology (CIC-1422), Department of Neurology, Hôpital Pitié-Salpêtrière, Paris, F-75013, France
| | - Olga Corti
- Institut du Cerveau et de la Moelle épinière, ICM, Paris, F-75013, France.,Inserm, U1127, Paris, F-75013, France.,CNRS, UMR 7225, Paris, F-75013, France.,Sorbonne Universités, Paris, F-75013, France
| |
Collapse
|
9
|
Schrenk C, Fetz V, Vallet C, Heiselmayer C, Schröder E, Hensel A, Hahlbrock A, Wünsch D, Goesswein D, Bier C, Habtemichael N, Schneider G, Stauber RH, Knauer SK. TFIIA transcriptional activity is controlled by a 'cleave-and-run' Exportin-1/Taspase 1-switch. J Mol Cell Biol 2018; 10:33-47. [PMID: 28992066 DOI: 10.1093/jmcb/mjx025] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2017] [Accepted: 07/09/2017] [Indexed: 12/24/2022] Open
Abstract
Transcription factor TFIIA is controlled by complex regulatory networks including proteolysis by the protease Taspase 1, though the full impact of cleavage remains elusive. Here, we demonstrate that in contrast to the general assumption, de novo produced TFIIA is rapidly confined to the cytoplasm via an evolutionary conserved nuclear export signal (NES, amino acids 21VINDVRDIFL30), interacting with the nuclear export receptor Exportin-1/chromosomal region maintenance 1 (Crm1). Chemical export inhibition or genetic inactivation of the NES not only promotes TFIIA's nuclear localization but also affects its transcriptional activity. Notably, Taspase 1 processing promotes TFIIA's nuclear accumulation by NES masking, and modulates its transcriptional activity. Moreover, TFIIA complex formation with the TATA box binding protein (TBP) is cooperatively enhanced by inhibition of proteolysis and nuclear export, leading to an increase of the cell cycle inhibitor p16INK, which is counteracted by prevention of TBP binding. We here identified a novel mechanism how proteolysis and nuclear transport cooperatively fine-tune transcriptional programs.
Collapse
Affiliation(s)
- Christian Schrenk
- Molecular and Cellular Oncology/ENT, University Hospital of Mainz, 55101 Mainz, Germany
| | - Verena Fetz
- Molecular and Cellular Oncology/ENT, University Hospital of Mainz, 55101 Mainz, Germany
| | - Cecilia Vallet
- Molecular Biology, Centre for Medical Biotechnology (ZMB), University Duisburg-Essen, 45141 Essen, Germany
| | - Christina Heiselmayer
- Molecular Biology, Centre for Medical Biotechnology (ZMB), University Duisburg-Essen, 45141 Essen, Germany
| | - Elisabeth Schröder
- Molecular Biology, Centre for Medical Biotechnology (ZMB), University Duisburg-Essen, 45141 Essen, Germany
| | - Astrid Hensel
- Molecular Biology, Centre for Medical Biotechnology (ZMB), University Duisburg-Essen, 45141 Essen, Germany
| | - Angelina Hahlbrock
- Molecular and Cellular Oncology/ENT, University Hospital of Mainz, 55101 Mainz, Germany
| | - Désirée Wünsch
- Molecular and Cellular Oncology/ENT, University Hospital of Mainz, 55101 Mainz, Germany
| | - Dorothee Goesswein
- Molecular and Cellular Oncology/ENT, University Hospital of Mainz, 55101 Mainz, Germany
| | - Carolin Bier
- Molecular and Cellular Oncology/ENT, University Hospital of Mainz, 55101 Mainz, Germany
| | - Negusse Habtemichael
- Molecular and Cellular Oncology/ENT, University Hospital of Mainz, 55101 Mainz, Germany
| | - Günter Schneider
- University Hospital Klinikum rechts der Isar, II. Medizinische Klinik, Technical University München, 81675 Munich, Germany
| | - Roland H Stauber
- Molecular and Cellular Oncology/ENT, University Hospital of Mainz, 55101 Mainz, Germany
| | - Shirley K Knauer
- Molecular Biology, Centre for Medical Biotechnology (ZMB), University Duisburg-Essen, 45141 Essen, Germany
| |
Collapse
|
10
|
Rizwan M, Mohd-Naim NF, Ahmed MU. Trends and Advances in Electrochemiluminescence Nanobiosensors. SENSORS (BASEL, SWITZERLAND) 2018; 18:E166. [PMID: 29315277 PMCID: PMC5795924 DOI: 10.3390/s18010166] [Citation(s) in RCA: 49] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/09/2017] [Revised: 01/03/2018] [Accepted: 01/06/2018] [Indexed: 12/11/2022]
Abstract
The rapid and increasing use of the nanomaterials (NMs), nanostructured materials (NSMs), metal nanoclusters (MNCs) or nanocomposites (NCs) in the development of electrochemiluminescence (ECL) nanobiosensors is a significant area of study for its massive potential in the practical application of nanobiosensor fabrication. Recently, NMs or NSMs (such as AuNPs, AgNPs, Fe₃O₄, CdS QDs, OMCs, graphene, CNTs and fullerenes) or MNCs (such as Au, Ag, and Pt) or NCs of both metallic and non-metallic origin are being employed for various purposes in the construction of biosensors. In this review, we have selected recently published articles (from 2014-2017) on the current development and prospects of label-free or direct ECL nanobiosensors that incorporate NCs, NMs, NSMs or MNCs.
Collapse
Affiliation(s)
- Mohammad Rizwan
- Biosensors and Biotechnology Laboratory, Chemical Science Programme, Faculty of Science, Universiti Brunei Darussalam, Jalan Tungku Link, Gadong BE 1410, Brunei Darussalam.
| | - Noor Faizah Mohd-Naim
- Biosensors and Biotechnology Laboratory, Chemical Science Programme, Faculty of Science, Universiti Brunei Darussalam, Jalan Tungku Link, Gadong BE 1410, Brunei Darussalam.
- Institute of Health Sciences, Universiti Brunei Darussalam, Jalan Tungku Link, Gadong BE 1410, Brunei Darussalam.
| | - Minhaz Uddin Ahmed
- Biosensors and Biotechnology Laboratory, Chemical Science Programme, Faculty of Science, Universiti Brunei Darussalam, Jalan Tungku Link, Gadong BE 1410, Brunei Darussalam.
| |
Collapse
|
11
|
Westmeier D, Hahlbrock A, Reinhardt C, Fröhlich-Nowoisky J, Wessler S, Vallet C, Pöschl U, Knauer SK, Stauber RH. Nanomaterial–microbe cross-talk: physicochemical principles and (patho)biological consequences. Chem Soc Rev 2018; 47:5312-5337. [DOI: 10.1039/c6cs00691d] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
NPs’ characteristics impact their spontaneous binding to microbes, which may affect the (patho)biological identity of both NP and microbes.
Collapse
Affiliation(s)
- D. Westmeier
- Department of Nanobiomedicine/ENT
- University Medical Center of Mainz
- 55101 Mainz
- Germany
| | - A. Hahlbrock
- Department of Nanobiomedicine/ENT
- University Medical Center of Mainz
- 55101 Mainz
- Germany
| | - C. Reinhardt
- Center for Thrombosis and Hemostasis
- University Medical Center Mainz
- 55101 Mainz
- Germany
| | - J. Fröhlich-Nowoisky
- Multiphase Chemistry Department
- Max Planck Institute for Chemistry
- 55128 Mainz
- Germany
| | - S. Wessler
- Department of Molecular Biology
- Paris-Lodron University of Salzburg
- A-5020 Salzburg
- Austria
| | - C. Vallet
- Institute for Molecular Biology
- CENIDE
- University Duisburg-Essen
- 45117 Essen
- Germany
| | - U. Pöschl
- Multiphase Chemistry Department
- Max Planck Institute for Chemistry
- 55128 Mainz
- Germany
| | - S. K. Knauer
- Institute for Molecular Biology
- CENIDE
- University Duisburg-Essen
- 45117 Essen
- Germany
| | - R. H. Stauber
- Department of Nanobiomedicine/ENT
- University Medical Center of Mainz
- 55101 Mainz
- Germany
| |
Collapse
|
12
|
Gribko A, Hahlbrock A, Strieth S, Becker S, Hagemann J, Deichelbohrer M, Hildebrandt A, Habtemichael N, Wünsch D. Disease-relevant signalling-pathways in head and neck cancer: Taspase1's proteolytic activity fine-tunes TFIIA function. Sci Rep 2017; 7:14937. [PMID: 29097782 PMCID: PMC5668323 DOI: 10.1038/s41598-017-14814-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2017] [Accepted: 10/16/2017] [Indexed: 12/23/2022] Open
Abstract
Head and neck cancer (HNC) is the seventh most common malignancy in the world and its prevailing form, the head and neck squamous cell carcinoma (HNSCC), is characterized as aggressive and invasive cancer type. The transcription factor II A (TFIIA), initially described as general regulator of RNA polymerase II-dependent transcription, is part of complex transcriptional networks also controlling mammalian head morphogenesis. Posttranslational cleavage of the TFIIA precursor by the oncologically relevant protease Taspase1 is crucial in this process. In contrast, the relevance of Taspase1-mediated TFIIA cleavage during oncogenesis of HNSCC is not characterized yet. Here, we performed genome-wide expression profiling of HNSCC which revealed significant downregulation of the TFIIA downstream target CDKN2A. To identify potential regulatory mechanisms of TFIIA on cellular level, we characterized nuclear-cytoplasmic transport and Taspase1-mediated cleavage of TFIIA variants. Unexpectedly, we identified an evolutionary conserved nuclear export signal (NES) counteracting nuclear localization and thus, transcriptional activity of TFIIA. Notably, proteolytic processing of TFIIA by Taspase1 was found to mask the NES, thereby promoting nuclear localization and transcriptional activation of TFIIA target genes, such as CDKN2A. Collectively, we here describe a hitherto unknown mechanism how cellular localization and Taspase1 cleavage fine-tunes transcriptional activity of TFIIA in HNSCC.
Collapse
Affiliation(s)
- Alena Gribko
- Department of Otorhinolaryngology, Molecular and Cellular Oncology, University Hospital of Mainz, Langenbeckstrasse 1, Mainz, 55101, Germany
| | - Angelina Hahlbrock
- Department of Otorhinolaryngology, Molecular and Cellular Oncology, University Hospital of Mainz, Langenbeckstrasse 1, Mainz, 55101, Germany
| | - Sebastian Strieth
- Department of Otorhinolaryngology, Molecular and Cellular Oncology, University Hospital of Mainz, Langenbeckstrasse 1, Mainz, 55101, Germany
| | - Sven Becker
- Department of Otorhinolaryngology, Molecular and Cellular Oncology, University Hospital of Mainz, Langenbeckstrasse 1, Mainz, 55101, Germany
| | - Jan Hagemann
- Department of Otorhinolaryngology, Molecular and Cellular Oncology, University Hospital of Mainz, Langenbeckstrasse 1, Mainz, 55101, Germany
| | - Max Deichelbohrer
- Department of Otorhinolaryngology, Molecular and Cellular Oncology, University Hospital of Mainz, Langenbeckstrasse 1, Mainz, 55101, Germany
| | - Andreas Hildebrandt
- Scientific Computing and Bioinformatics, Johannes Gutenberg University, Staudingerweg 9, Mainz, 55128, Germany
| | - Negusse Habtemichael
- Department of Otorhinolaryngology, Molecular and Cellular Oncology, University Hospital of Mainz, Langenbeckstrasse 1, Mainz, 55101, Germany
| | - D Wünsch
- Department of Otorhinolaryngology, Molecular and Cellular Oncology, University Hospital of Mainz, Langenbeckstrasse 1, Mainz, 55101, Germany.
| |
Collapse
|
13
|
Translocation Biosensors-Versatile Tools to Probe Protein Functions in Living Cells. Methods Mol Biol 2017. [PMID: 29082494 DOI: 10.1007/978-1-4939-7357-6_12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register]
Abstract
In this chapter, you will learn how to use translocation biosensors to investigate protein functions in living cells. We here present three classes of modular protein translocation biosensors tailored to investigate: (1) signal-mediated nucleo-cytoplasmic transport, (2) protease activity, and (3) protein-protein interactions. Besides the mapping of protein function, the biosensors are also applicable to identify chemicals and/or (nano) materials modulating the respective protein activities and can also be exploited for RNAi-mediated genetic screens.
Collapse
|
14
|
García-Santisteban I, Arregi I, Alonso-Mariño M, Urbaneja MA, Garcia-Vallejo JJ, Bañuelos S, Rodríguez JA. A cellular reporter to evaluate CRM1 nuclear export activity: functional analysis of the cancer-related mutant E571K. Cell Mol Life Sci 2016; 73:4685-4699. [PMID: 27312238 PMCID: PMC11108298 DOI: 10.1007/s00018-016-2292-0] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2016] [Revised: 05/10/2016] [Accepted: 06/07/2016] [Indexed: 01/02/2023]
Abstract
The exportin CRM1 binds nuclear export signals (NESs), and mediates active transport of NES-bearing proteins from the nucleus to the cytoplasm. Structural and biochemical analyses have uncovered the molecular mechanisms underlying CRM1/NES interaction. CRM1 binds NESs through a hydrophobic cleft, whose open or closed conformation facilitates NES binding and release. Several cofactors allosterically modulate the conformation of the NES-binding cleft through intramolecular interactions involving an acidic loop and a C-terminal helix in CRM1. This current model of CRM1-mediated nuclear export has not yet been evaluated in a cellular setting. Here, we describe SRV100, a cellular reporter to interrogate CRM1 nuclear export activity. Using this novel tool, we provide evidence further validating the model of NES binding and release by CRM1. Furthermore, using both SRV100-based cellular assays and in vitro biochemical analyses, we investigate the functional consequences of a recurrent cancer-related mutation, which targets a residue near CRM1 NES-binding cleft. Our data indicate that this mutation does not necessarily abrogate the nuclear export activity of CRM1, but may increase its affinity for NES sequences bearing a more negatively charged C-terminal end.
Collapse
Affiliation(s)
- Iraia García-Santisteban
- Department of Genetics, Physical Anthropology and Animal Physiology, University of the Basque Country (UPV/EHU), Leioa, Spain
- Division of Cell Biology I, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Igor Arregi
- Department of Biochemistry and Molecular Biology, Biofisika Institute (UPV/EHU, CSIC), University of the Basque Country, Leioa, Spain
| | - Marián Alonso-Mariño
- Department of Biochemistry and Molecular Biology, Biofisika Institute (UPV/EHU, CSIC), University of the Basque Country, Leioa, Spain
| | - María A Urbaneja
- Department of Biochemistry and Molecular Biology, Biofisika Institute (UPV/EHU, CSIC), University of the Basque Country, Leioa, Spain
| | - Juan J Garcia-Vallejo
- Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands
| | - Sonia Bañuelos
- Department of Biochemistry and Molecular Biology, Biofisika Institute (UPV/EHU, CSIC), University of the Basque Country, Leioa, Spain.
| | - Jose A Rodríguez
- Department of Genetics, Physical Anthropology and Animal Physiology, University of the Basque Country (UPV/EHU), Leioa, Spain.
| |
Collapse
|
15
|
Wünsch D, Hahlbrock A, Heiselmayer C, Bäcker S, Heun P, Goesswein D, Stöcker W, Schirmeister T, Schneider G, Krämer OH, Knauer SK, Stauber RH. Fly versus man: evolutionary impairment of nucleolar targeting affects the degradome of Drosophila's Taspase1. FASEB J 2015; 29:1973-85. [PMID: 25634959 DOI: 10.1096/fj.14-262451] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2014] [Accepted: 12/29/2014] [Indexed: 12/12/2022]
Abstract
Human Taspase1 is essential for development and cancer by processing critical regulators, such as the mixed-lineage leukemia protein. Likewise, its ortholog, trithorax, is cleaved by Drosophila Taspase1 (dTaspase1), implementing a functional coevolution. To uncover novel mechanism regulating protease function, we performed a functional analysis of dTaspase1 and its comparison to the human ortholog. dTaspase1 contains an essential nucleophile threonine(195), catalyzing cis cleavage into its α- and β-subunits. A cell-based assay combined with alanine scanning mutagenesis demonstrated that the target cleavage motif for dTaspase1 (Q(3)[F/I/L/M](2)D(1)↓G(1')X(2')X(3')) differs significantly from the human ortholog (Q(3)[F,I,L,V](2)D(1)↓G(1')x(2')D(3')D(4')), predicting an enlarged degradome containing 70 substrates for Drosophila. In contrast to human Taspase1, dTaspase1 shows no discrete localization to the nucleus/nucleolus due to the lack of the importin-α/nucleophosmin1 interaction domain (NoLS) conserved in all vertebrates. Consequently, dTaspase1 interacts with neither the Drosophila nucleoplasmin-like protein nor human nucleophosmin1. The impact of localization on the protease's degradome was confirmed by demonstrating that dTaspase1 did not efficiently process nuclear substrates, such as upstream stimulatory factor 2. However, genetic introduction of the NoLS into dTaspase1 restored its nucleolar localization, nucleophosmin1 interaction, and efficient cleavage of nuclear substrates. We report that evolutionary functional divergence separating vertebrates from invertebrates can be achieved for proteases by a transport/localization-regulated mechanism.
Collapse
Affiliation(s)
- Désirée Wünsch
- *Molecular and Cellular Oncology, Ear, Nose and Throat Department, University Medical Center of Mainz, Mainz, Germany; Institute for Molecular Biology, Centre for Medical Biotechnology, Mainz Scientific Screening Center UG & Co. KG, University of Duisburg-Essen, Essen, Germany; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany; Cell and Matrix Biology, Institute for Zoology, and Institute for Pharmacy and Biochemistry, University of Mainz, Mainz, Germany; II. Medizinische Klinik, Technische Universität München, Munich, Germany; and Department of Toxicology, University Medical Center, Mainz, Germany
| | - Angelina Hahlbrock
- *Molecular and Cellular Oncology, Ear, Nose and Throat Department, University Medical Center of Mainz, Mainz, Germany; Institute for Molecular Biology, Centre for Medical Biotechnology, Mainz Scientific Screening Center UG & Co. KG, University of Duisburg-Essen, Essen, Germany; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany; Cell and Matrix Biology, Institute for Zoology, and Institute for Pharmacy and Biochemistry, University of Mainz, Mainz, Germany; II. Medizinische Klinik, Technische Universität München, Munich, Germany; and Department of Toxicology, University Medical Center, Mainz, Germany
| | - Christina Heiselmayer
- *Molecular and Cellular Oncology, Ear, Nose and Throat Department, University Medical Center of Mainz, Mainz, Germany; Institute for Molecular Biology, Centre for Medical Biotechnology, Mainz Scientific Screening Center UG & Co. KG, University of Duisburg-Essen, Essen, Germany; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany; Cell and Matrix Biology, Institute for Zoology, and Institute for Pharmacy and Biochemistry, University of Mainz, Mainz, Germany; II. Medizinische Klinik, Technische Universität München, Munich, Germany; and Department of Toxicology, University Medical Center, Mainz, Germany
| | - Sandra Bäcker
- *Molecular and Cellular Oncology, Ear, Nose and Throat Department, University Medical Center of Mainz, Mainz, Germany; Institute for Molecular Biology, Centre for Medical Biotechnology, Mainz Scientific Screening Center UG & Co. KG, University of Duisburg-Essen, Essen, Germany; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany; Cell and Matrix Biology, Institute for Zoology, and Institute for Pharmacy and Biochemistry, University of Mainz, Mainz, Germany; II. Medizinische Klinik, Technische Universität München, Munich, Germany; and Department of Toxicology, University Medical Center, Mainz, Germany
| | - Patrick Heun
- *Molecular and Cellular Oncology, Ear, Nose and Throat Department, University Medical Center of Mainz, Mainz, Germany; Institute for Molecular Biology, Centre for Medical Biotechnology, Mainz Scientific Screening Center UG & Co. KG, University of Duisburg-Essen, Essen, Germany; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany; Cell and Matrix Biology, Institute for Zoology, and Institute for Pharmacy and Biochemistry, University of Mainz, Mainz, Germany; II. Medizinische Klinik, Technische Universität München, Munich, Germany; and Department of Toxicology, University Medical Center, Mainz, Germany
| | - Dorothee Goesswein
- *Molecular and Cellular Oncology, Ear, Nose and Throat Department, University Medical Center of Mainz, Mainz, Germany; Institute for Molecular Biology, Centre for Medical Biotechnology, Mainz Scientific Screening Center UG & Co. KG, University of Duisburg-Essen, Essen, Germany; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany; Cell and Matrix Biology, Institute for Zoology, and Institute for Pharmacy and Biochemistry, University of Mainz, Mainz, Germany; II. Medizinische Klinik, Technische Universität München, Munich, Germany; and Department of Toxicology, University Medical Center, Mainz, Germany
| | - Walter Stöcker
- *Molecular and Cellular Oncology, Ear, Nose and Throat Department, University Medical Center of Mainz, Mainz, Germany; Institute for Molecular Biology, Centre for Medical Biotechnology, Mainz Scientific Screening Center UG & Co. KG, University of Duisburg-Essen, Essen, Germany; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany; Cell and Matrix Biology, Institute for Zoology, and Institute for Pharmacy and Biochemistry, University of Mainz, Mainz, Germany; II. Medizinische Klinik, Technische Universität München, Munich, Germany; and Department of Toxicology, University Medical Center, Mainz, Germany
| | - Tanja Schirmeister
- *Molecular and Cellular Oncology, Ear, Nose and Throat Department, University Medical Center of Mainz, Mainz, Germany; Institute for Molecular Biology, Centre for Medical Biotechnology, Mainz Scientific Screening Center UG & Co. KG, University of Duisburg-Essen, Essen, Germany; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany; Cell and Matrix Biology, Institute for Zoology, and Institute for Pharmacy and Biochemistry, University of Mainz, Mainz, Germany; II. Medizinische Klinik, Technische Universität München, Munich, Germany; and Department of Toxicology, University Medical Center, Mainz, Germany
| | - Günter Schneider
- *Molecular and Cellular Oncology, Ear, Nose and Throat Department, University Medical Center of Mainz, Mainz, Germany; Institute for Molecular Biology, Centre for Medical Biotechnology, Mainz Scientific Screening Center UG & Co. KG, University of Duisburg-Essen, Essen, Germany; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany; Cell and Matrix Biology, Institute for Zoology, and Institute for Pharmacy and Biochemistry, University of Mainz, Mainz, Germany; II. Medizinische Klinik, Technische Universität München, Munich, Germany; and Department of Toxicology, University Medical Center, Mainz, Germany
| | - Oliver H Krämer
- *Molecular and Cellular Oncology, Ear, Nose and Throat Department, University Medical Center of Mainz, Mainz, Germany; Institute for Molecular Biology, Centre for Medical Biotechnology, Mainz Scientific Screening Center UG & Co. KG, University of Duisburg-Essen, Essen, Germany; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany; Cell and Matrix Biology, Institute for Zoology, and Institute for Pharmacy and Biochemistry, University of Mainz, Mainz, Germany; II. Medizinische Klinik, Technische Universität München, Munich, Germany; and Department of Toxicology, University Medical Center, Mainz, Germany
| | - Shirley K Knauer
- *Molecular and Cellular Oncology, Ear, Nose and Throat Department, University Medical Center of Mainz, Mainz, Germany; Institute for Molecular Biology, Centre for Medical Biotechnology, Mainz Scientific Screening Center UG & Co. KG, University of Duisburg-Essen, Essen, Germany; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany; Cell and Matrix Biology, Institute for Zoology, and Institute for Pharmacy and Biochemistry, University of Mainz, Mainz, Germany; II. Medizinische Klinik, Technische Universität München, Munich, Germany; and Department of Toxicology, University Medical Center, Mainz, Germany
| | - Roland H Stauber
- *Molecular and Cellular Oncology, Ear, Nose and Throat Department, University Medical Center of Mainz, Mainz, Germany; Institute for Molecular Biology, Centre for Medical Biotechnology, Mainz Scientific Screening Center UG & Co. KG, University of Duisburg-Essen, Essen, Germany; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany; Cell and Matrix Biology, Institute for Zoology, and Institute for Pharmacy and Biochemistry, University of Mainz, Mainz, Germany; II. Medizinische Klinik, Technische Universität München, Munich, Germany; and Department of Toxicology, University Medical Center, Mainz, Germany
| |
Collapse
|
16
|
Docter D, Bantz C, Westmeier D, Galla HJ, Wang Q, Kirkpatrick JC, Nielsen P, Maskos M, Stauber RH. The protein corona protects against size- and dose-dependent toxicity of amorphous silica nanoparticles. BEILSTEIN JOURNAL OF NANOTECHNOLOGY 2014; 5:1380-92. [PMID: 25247121 PMCID: PMC4168937 DOI: 10.3762/bjnano.5.151] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/18/2014] [Accepted: 08/07/2014] [Indexed: 05/24/2023]
Abstract
Besides the lung and skin, the gastrointestinal (GI) tract is one of the main targets for accidental exposure or biomedical applications of nanoparticles (NP). Biological responses to NP, including nanotoxicology, are caused by the interaction of the NP with cellular membranes and/or cellular entry. Here, the physico-chemical characteristics of NP are widely discussed as critical determinants, albeit the exact mechanisms remain to be resolved. Moreover, proteins associate with NP in physiological fluids, forming the protein corona potentially transforming the biological identity of the particle and thus, adding an additional level of complexity for the bio-nano responses. Here, we employed amorphous silica nanoparticles (ASP) and epithelial GI tract Caco-2 cells as a model to study the biological impact of particle size as well as of the protein corona. Caco-2 or mucus-producing HT-29 cells were exposed to thoroughly characterized, negatively charged ASP of different size in the absence or presence of proteins. Comprehensive experimental approaches, such as quantifying cellular metabolic activity, microscopic observation of cell morphology, and high-throughput cell analysis revealed a dose- and time-dependent toxicity primarily upon exposure with ASP30 (Ø = 30 nm). Albeit smaller (ASP20, Ø = 20 nm) or larger particles (ASP100; Ø = 100 nm) showed a similar zeta potential, they both displayed only low toxicity. Importantly, the adverse effects triggered by ASP30/ASP30L were significantly ameliorated upon formation of the protein corona, which we found was efficiently established on all ASP studied. As a potential explanation, corona formation reduced ASP30 cellular uptake, which was however not significantly affected by ASP surface charge in our model. Collectively, our study uncovers an impact of ASP size as well as of the protein corona on cellular toxicity, which might be relevant for processes at the nano-bio interface in general.
Collapse
Affiliation(s)
- Dominic Docter
- Molecular and Cellular Oncology, ENT/University Medical Center Mainz, Langenbeckstr. 1, 55101 Mainz, Germany
| | - Christoph Bantz
- Fraunhofer ICT-IMM, Carl-Zeiss-Str. 18-20, 55129 Mainz, Germany
| | - Dana Westmeier
- Molecular and Cellular Oncology, ENT/University Medical Center Mainz, Langenbeckstr. 1, 55101 Mainz, Germany
| | - Hajo J Galla
- Institute of Biochemistry, Westfälische Wilhelms-University, Wilhelm Klemm-Str. 2, 48149 Münster, Germany
| | - Qiangbin Wang
- Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, 215123 China
| | - James C Kirkpatrick
- Institute of Pathology, University Medical Centre, Institute of Pathology, Langenbeckstr. 1, 55101 Mainz, Germany
| | - Peter Nielsen
- Department of Biochemistry and Molecular Cell Biology, University Medical Center Hamburg-Eppendorf, Germany
| | - Michael Maskos
- Fraunhofer ICT-IMM, Carl-Zeiss-Str. 18-20, 55129 Mainz, Germany
| | - Roland H Stauber
- Molecular and Cellular Oncology, ENT/University Medical Center Mainz, Langenbeckstr. 1, 55101 Mainz, Germany
| |
Collapse
|
17
|
Ginter T, Fahrer J, Kröhnert U, Fetz V, Garrone A, Stauber RH, Reichardt W, Müller-Newen G, Kosan C, Heinzel T, Krämer OH. Arginine residues within the DNA binding domain of STAT3 promote intracellular shuttling and phosphorylation of STAT3. Cell Signal 2014; 26:1698-706. [PMID: 24721162 DOI: 10.1016/j.cellsig.2014.03.033] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2013] [Revised: 03/20/2014] [Accepted: 03/31/2014] [Indexed: 01/10/2023]
Abstract
Acetylation-dependent inactivation of STAT1 can be mimicked by the exchange of its lysine residues K410 and K413 to glutamine residues. STAT3 harbors non-acetylatable arginine moieties at the corresponding sites R414 and R417. It is unclear whether the mutation of these sites to glutamine residues antagonizes STAT3 activation. Here, we show that an arginine-glutamine-exchange at the STAT3 moieties R414 and R417 (R414Q and R417Q) reduces cytokine-dependent tyrosine phosphorylation of STAT3. This inhibitory effect can be partially rescued by phosphatase inhibition. In addition, the R414Q and R417Q mutations enhance the nuclear accumulation of unphosphorylated STAT3. STAT3 R414Q and STAT3 R417Q show a reduced response to cytokine stimulation emanating from the plasma membrane. Moreover, these STAT3 mutants have no direct inhibitory effect on the cytokine-induced activation of STAT1/STAT3-mediated gene expression. Since the mutations R414Q and R417Q reside within the STAT3 DNA binding domain (DBD), the STAT3 R414Q and R417Q mutants also lack intrinsic activity as transcription factors. Furthermore, in contrast to wild-type STAT3 they cannot compensate for a loss of STAT1 and they cannot promote STAT1/STAT3-dependent transcriptional activation. We further analyzed a STAT3 arginine-lysine-exchange mutant (R414K/R417K). This molecule mimics corresponding lysine residues found within the DBD of STAT1. Compared to wild-type STAT3, the STAT3 R414K/R417K mutant shows attenuated tyrosine phosphorylation and it is a less active transcription factor. In addition, STAT3 R414K/R417K is not activated by deacetylase inhibition. On the other hand, C-terminal acetylation of STAT3 is intact in STAT3 R414K/R417K. Our results suggest that the exchange of amino acid residues within the DBDs of STAT1/STAT3 affects their phosphorylation as well as their intracellular shuttling.
Collapse
Affiliation(s)
- Torsten Ginter
- Center for Molecular Biomedicine (CMB), Dept. of Biochemistry, University of Jena, Germany
| | - Jörg Fahrer
- Department of Toxicology, University Medical Center, Obere Zahlbacher Str. 67, 55131 Mainz, Germany
| | - Ulrike Kröhnert
- Center for Molecular Biomedicine (CMB), Dept. of Biochemistry, University of Jena, Germany
| | - Verena Fetz
- Department of Molecular and Cellular Oncology, University Hospital, Mainz, Germany
| | - Alessio Garrone
- Center for Molecular Biomedicine (CMB), Dept. of Biochemistry, University of Jena, Germany
| | - Roland H Stauber
- Department of Molecular and Cellular Oncology, University Hospital, Mainz, Germany
| | - Werner Reichardt
- University of Applied Sciences Jena, Department of Medical Engineering and Biotechnology, 07745 Jena, Germany
| | - Gerhard Müller-Newen
- Institute of Biochemistry and Molecular Biology, RWTH Aachen University, 52074 Aachen, Germany
| | - Christian Kosan
- Center for Molecular Biomedicine (CMB), Dept. of Biochemistry, University of Jena, Germany
| | - Thorsten Heinzel
- Center for Molecular Biomedicine (CMB), Dept. of Biochemistry, University of Jena, Germany
| | - Oliver H Krämer
- Department of Toxicology, University Medical Center, Obere Zahlbacher Str. 67, 55131 Mainz, Germany.
| |
Collapse
|
18
|
Biosensors in clinical practice: focus on oncohematology. SENSORS 2013; 13:6423-47. [PMID: 23673681 PMCID: PMC3690064 DOI: 10.3390/s130506423] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/06/2013] [Revised: 04/15/2013] [Accepted: 04/18/2013] [Indexed: 02/07/2023]
Abstract
Biosensors are devices that are capable of detecting specific biological analytes and converting their presence or concentration into some electrical, thermal, optical or other signal that can be easily analysed. The first biosensor was designed by Clark and Lyons in 1962 as a means of measuring glucose. Since then, much progress has been made and the applications of biosensors are today potentially boundless. This review is limited to their clinical applications, particularly in the field of oncohematology. Biosensors have recently been developed in order to improve the diagnosis and treatment of patients affected by hematological malignancies, such as the biosensor for assessing the in vitro pre-treatment efficacy of cytarabine in acute myeloid leukemia, and the fluorescence resonance energy transfer-based biosensor for assessing the efficacy of imatinib in chronic myeloid leukemia. The review also considers the challenges and future perspectives of biosensors in clinical practice.
Collapse
|
19
|
Knauer SK, Fetz V, Rabenstein J, Friedl S, Hofmann B, Sabiani S, Schröder E, Kunst L, Proschak E, Thines E, Kindler T, Schneider G, Marschalek R, Stauber RH, Bier C. Bioassays to monitor Taspase1 function for the identification of pharmacogenetic inhibitors. PLoS One 2011; 6:e18253. [PMID: 21647428 PMCID: PMC3102056 DOI: 10.1371/journal.pone.0018253] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2010] [Accepted: 02/28/2011] [Indexed: 12/12/2022] Open
Abstract
Background Threonine Aspartase 1 (Taspase1) mediates cleavage of the mixed lineage leukemia (MLL) protein and leukemia provoking MLL-fusions. In contrast to other proteases, the understanding of Taspase1's (patho)biological relevance and function is limited, since neither small molecule inhibitors nor cell based functional assays for Taspase1 are currently available. Methodology/Findings Efficient cell-based assays to probe Taspase1 function in vivo are presented here. These are composed of glutathione S-transferase, autofluorescent protein variants, Taspase1 cleavage sites and rational combinations of nuclear import and export signals. The biosensors localize predominantly to the cytoplasm, whereas expression of biologically active Taspase1 but not of inactive Taspase1 mutants or of the protease Caspase3 triggers their proteolytic cleavage and nuclear accumulation. Compared to in vitro assays using recombinant components the in vivo assay was highly efficient. Employing an optimized nuclear translocation algorithm, the triple-color assay could be adapted to a high-throughput microscopy platform (Z'factor = 0.63). Automated high-content data analysis was used to screen a focused compound library, selected by an in silico pharmacophor screening approach, as well as a collection of fungal extracts. Screening identified two compounds, N-[2-[(4-amino-6-oxo-3H-pyrimidin-2-yl)sulfanyl]ethyl]benzenesulfonamide and 2-benzyltriazole-4,5-dicarboxylic acid, which partially inhibited Taspase1 cleavage in living cells. Additionally, the assay was exploited to probe endogenous Taspase1 in solid tumor cell models and to identify an improved consensus sequence for efficient Taspase1 cleavage. This allowed the in silico identification of novel putative Taspase1 targets. Those include the FERM Domain-Containing Protein 4B, the Tyrosine-Protein Phosphatase Zeta, and DNA Polymerase Zeta. Cleavage site recognition and proteolytic processing of these substrates were verified in the context of the biosensor. Conclusions The assay not only allows to genetically probe Taspase1 structure function in vivo, but is also applicable for high-content screening to identify Taspase1 inhibitors. Such tools will provide novel insights into Taspase1's function and its potential therapeutic relevance.
Collapse
Affiliation(s)
- Shirley K. Knauer
- Institute for Molecular Biology, Centre for Medical Biotechnology (ZMB), University Duisburg-Essen, Essen, Germany
| | - Verena Fetz
- Mainzer Screening Center (MSC), University Medical Center of the Johannes Gutenberg-University of Mainz, Mainz, Germany
| | - Jens Rabenstein
- Institute of Pharmaceutical Biology/ZAFES, Goethe-University, Frankfurt/Main, Germany
| | - Sandra Friedl
- Mainzer Screening Center (MSC), University Medical Center of the Johannes Gutenberg-University of Mainz, Mainz, Germany
| | - Bettina Hofmann
- Institute Organic Chemistry and Chemical Biology/ZAFES, Goethe-University, Frankfurt/Main, Germany
| | - Samaneh Sabiani
- Institute of Pharmaceutical Biology/ZAFES, Goethe-University, Frankfurt/Main, Germany
| | - Elisabeth Schröder
- Institute for Molecular Biology, Centre for Medical Biotechnology (ZMB), University Duisburg-Essen, Essen, Germany
| | - Lena Kunst
- Institute for Molecular Biology, Centre for Medical Biotechnology (ZMB), University Duisburg-Essen, Essen, Germany
| | - Eugen Proschak
- Institute Organic Chemistry and Chemical Biology/ZAFES, Goethe-University, Frankfurt/Main, Germany
| | - Eckhard Thines
- Institute of Biotechnology and Drug Research Kaiserslautern (IBWF), Kaiserslautern, Germany
| | - Thomas Kindler
- Department of Hematology/Oncology, University Medical Center of the Johannes Gutenberg-University of Mainz, Mainz, Germany
| | - Gisbert Schneider
- Institute Organic Chemistry and Chemical Biology/ZAFES, Goethe-University, Frankfurt/Main, Germany
| | - Rolf Marschalek
- Institute of Pharmaceutical Biology/ZAFES, Goethe-University, Frankfurt/Main, Germany
| | - Roland H. Stauber
- Mainzer Screening Center (MSC), University Medical Center of the Johannes Gutenberg-University of Mainz, Mainz, Germany
- * E-mail: (CB); (RHS)
| | - Carolin Bier
- Mainzer Screening Center (MSC), University Medical Center of the Johannes Gutenberg-University of Mainz, Mainz, Germany
- * E-mail: (CB); (RHS)
| |
Collapse
|
20
|
Bier C, Knauer SK, Docter D, Schneider G, Krämer OH, Stauber RH. The Importin-Alpha/Nucleophosmin Switch Controls Taspase1 Protease Function. Traffic 2011; 12:703-14. [DOI: 10.1111/j.1600-0854.2011.01191.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
21
|
Bier C, Knauer SK, Klapthor A, Schweitzer A, Rekik A, Krämer OH, Marschalek R, Stauber RH. Cell-based analysis of structure-function activity of threonine aspartase 1. J Biol Chem 2011; 286:3007-17. [PMID: 21084304 PMCID: PMC3024795 DOI: 10.1074/jbc.m110.161646] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2010] [Revised: 10/22/2010] [Indexed: 12/24/2022] Open
Abstract
Taspase1 is a threonine protease responsible for cleaving intracellular substrates. As such, (de)regulated Taspase1 function is expected not only to be vital for ordered development but may also be relevant for disease. However, the full repertoires of Taspase1 targets as well as the exact biochemical requirements for its efficient and substrate-specific cleavage are not yet resolved. Also, no cellular assays for this protease are currently available, hampering the exploitation of the (patho)biological relevance of Taspase1. Here, we developed highly efficient cell-based translocation biosensor assays to probe Taspase1 trans-cleavage in vivo. These modular sensors harbor variations of Taspase1 cleavage sites and localize to the cytoplasm. Expression of Taspase1 but not of inactive Taspase1 mutants or of unrelated proteases triggers proteolytic cleavage and nuclear accumulation of the biosensors. Employing our assay combined with scanning mutagenesis, we identified the sequence and spatial requirements for efficient Taspase1 processing in liquid and solid tumor cell lines. Collectively, our results defined an improved Taspase1 consensus recognition sequence, Q(3)(F/I/L/V)(2)D(1)↓G(1)'X(2)'D(3)'D(4)', allowing the first genome-wide bioinformatic identification of the human Taspase1 degradome. Among the 27 most likely Taspase1 targets are cytoplasmic but also nuclear proteins, such as the upstream stimulatory factor 2 (USF2) or the nuclear RNA export factors 2/5 (NXF2/5). Cleavage site recognition and proteolytic processing of selected targets were verified in the context of the biosensor and for the full-length proteins. We provide novel mechanistic insights into the function and bona fide targets of Taspase1 allowing for a focused investigation of the (patho)biological relevance of this type 2 asparaginase.
Collapse
Affiliation(s)
- Carolin Bier
- From the Molecular and Cellular Oncology/Mainzer Screening Center, University Hospital of Mainz, Langenbeckstrasse 1, 55101 Mainz
| | - Shirley K. Knauer
- the Institute for Molecular Biology, Centre for Medical Biotechnology, University Duisburg-Essen, Universitätsstrasse, 45117 Essen
| | - Alexander Klapthor
- From the Molecular and Cellular Oncology/Mainzer Screening Center, University Hospital of Mainz, Langenbeckstrasse 1, 55101 Mainz
| | - Andrea Schweitzer
- From the Molecular and Cellular Oncology/Mainzer Screening Center, University Hospital of Mainz, Langenbeckstrasse 1, 55101 Mainz
| | - Alexander Rekik
- From the Molecular and Cellular Oncology/Mainzer Screening Center, University Hospital of Mainz, Langenbeckstrasse 1, 55101 Mainz
| | - Oliver H. Krämer
- the Institute for Biochemistry and Biophysics/Centre for Molecular Biomedicine, Friedrich-Schiller-University Jena, Hans-Knöll-Strasse 2, 07745 Jena, and
| | - Rolf Marschalek
- the Institute for Pharmaceutical Biology/ZAFES, Goethe-University, Max-von Laue-Strasse 9, 60438 Frankfurt/Main, Germany
| | - Roland H. Stauber
- From the Molecular and Cellular Oncology/Mainzer Screening Center, University Hospital of Mainz, Langenbeckstrasse 1, 55101 Mainz
| |
Collapse
|
22
|
Lee KB, Hwang JM, Choi IS, Rho J, Choi JS, Kim GH, Kim SI, Kim S, Lee ZW. Direct Monitoring of the Inhibition of Protein-Protein Interactions in Cells by Translocation of PKCδ Fusion Proteins. Angew Chem Int Ed Engl 2011. [DOI: 10.1002/ange.201005333] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
23
|
Lee KB, Hwang JM, Choi IS, Rho J, Choi JS, Kim GH, Kim SI, Kim S, Lee ZW. Direct Monitoring of the Inhibition of Protein-Protein Interactions in Cells by Translocation of PKCδ Fusion Proteins. Angew Chem Int Ed Engl 2011; 50:1314-7. [DOI: 10.1002/anie.201005333] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2010] [Indexed: 11/09/2022]
|
24
|
Habtemichael N, Wünsch D, Bier C, Tillmann S, Unruhe B, Frauenknecht K, Heinrich UR, Mann WJ, Stauber RH, Knauer SK. Cloning and functional characterization of the guinea pig apoptosis inhibitor protein Survivin. Gene 2010; 469:9-17. [DOI: 10.1016/j.gene.2010.08.007] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2010] [Revised: 08/08/2010] [Accepted: 08/09/2010] [Indexed: 11/29/2022]
|
25
|
Expression analysis suggests a potential cytoprotective role of Birc5 in the inner ear. Mol Cell Neurosci 2010; 45:297-305. [DOI: 10.1016/j.mcn.2010.07.003] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2010] [Revised: 06/28/2010] [Accepted: 07/06/2010] [Indexed: 11/19/2022] Open
|
26
|
Knauer SK, Heinrich UR, Bier C, Habtemichael N, Docter D, Helling K, Mann WJ, Stauber RH. An otoprotective role for the apoptosis inhibitor protein survivin. Cell Death Dis 2010; 1:e51. [PMID: 21364656 PMCID: PMC3032560 DOI: 10.1038/cddis.2010.25] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Hearing impairment caused by ototoxic insults, such as noise or gentamicin is a worldwide health problem. As the molecular circuitries involved are not yet resolved, current otoprotective therapies are rather empirical than rational. Here, immunohistochemistry and western blotting showed that the cytoprotective protein survivin is expressed in the human and guinea pig cochlea. In the guinea pig model, moderate noise exposure causing only a temporary hearing impairment transiently evoked survivin expression in the spiral ligament, nerve fibers and the organ of Corti. Mechanistically, survivin upregulation may involve nitric oxide (NO)-induced Akt signaling, as enhanced expression of the endothelial NO synthase and phosphorylated Akt were detectable in some surviving-positive cell types. In contrast, intratympanic gentamicin injection inducing cell damage and permanent hearing loss correlated with attenuated survivin levels in the cochlea. Subsequently, the protective activity of the human and the guinea pig survivin orthologs against the ototoxin gentamicin was demonstrated by ectopic overexpression and RNAi-mediated depletion studies in auditory cells in vitro. These data suggest that survivin represents an innate cytoprotective resistor against stress conditions in the auditory system. The pharmacogenetic modulation of survivin may thus provide the conceptual basis for the rational design of novel therapeutic otoprotective strategies.
Collapse
Affiliation(s)
- S K Knauer
- Department of Molecular and Cellular Oncology, University Hospital of Mainz, Mainz, Germany
| | | | | | | | | | | | | | | |
Collapse
|